- Home
- HRMY vs GDRX Comparison
HRMY vs GDRX Comparison
Compare HRMY & GDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- GDRX
- Stock Information
- Founded
- HRMY 2017
- GDRX 2011
- Country
- HRMY United States
- GDRX United States
- Employees
- HRMY N/A
- GDRX N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- GDRX Retail: Computer Software & Peripheral Equipment
- Sector
- HRMY Health Care
- GDRX Technology
- Exchange
- HRMY Nasdaq
- GDRX Nasdaq
- Market Cap
- HRMY 1.6B
- GDRX N/A
- IPO Year
- HRMY 2020
- GDRX 2020
- Fundamental
- Price
- HRMY $34.09
- GDRX $4.24
- Analyst Decision
- HRMY Strong Buy
- GDRX Buy
- Analyst Count
- HRMY 8
- GDRX 11
- Target Price
- HRMY $52.88
- GDRX $8.30
- AVG Volume (30 Days)
- HRMY 729.2K
- GDRX 1.5M
- Earning Date
- HRMY 05-06-2025
- GDRX 05-07-2025
- Dividend Yield
- HRMY N/A
- GDRX N/A
- EPS Growth
- HRMY 13.13
- GDRX N/A
- EPS
- HRMY 2.62
- GDRX 0.07
- Revenue
- HRMY $744,852,000.00
- GDRX $797,414,000.00
- Revenue This Year
- HRMY $20.06
- GDRX $5.98
- Revenue Next Year
- HRMY $18.40
- GDRX $6.38
- P/E Ratio
- HRMY $12.76
- GDRX $58.81
- Revenue Growth
- HRMY 20.62
- GDRX 4.35
- 52 Week Low
- HRMY $26.47
- GDRX $3.82
- 52 Week High
- HRMY $41.61
- GDRX $9.26
- Technical
- Relative Strength Index (RSI)
- HRMY 69.87
- GDRX 44.46
- Support Level
- HRMY $29.82
- GDRX $3.68
- Resistance Level
- HRMY $30.61
- GDRX $4.80
- Average True Range (ATR)
- HRMY 1.15
- GDRX 0.25
- MACD
- HRMY 0.71
- GDRX -0.05
- Stochastic Oscillator
- HRMY 98.91
- GDRX 48.50
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.